APH-1501 — Competitive Intelligence Brief

APH-1501 (APH-1501) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cannabinoid. Area: Pain.

phase 2 cannabinoid CB1/CB2 receptors Pain Small molecule

Target snapshot

APH-1501 (APH-1501) — Aphios. APH-1501 is a cannabinoid-based therapy.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
APH-1501 TARGET	APH-1501	Aphios	phase 2	cannabinoid	CB1/CB2 receptors
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
CimetrA-2	CimetrA-2	MGC Pharmaceuticals d.o.o	phase 3	cannabinoid receptor agonist	CB1/CB2 receptors
Marinol	DRONABINOL	Wellhouse Pharma	marketed	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
Cannabidiol oral oil	Cannabidiol oral oil	Hôpital le Vinatier	marketed	Cannabinoid	Multiple (5-HT1A, TRPV1, CB1, CB2, glycine receptors)
Hemp	Hemp	Thammasat University Hospital	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cannabinoid class)

1. Aphios · 1 drug in this class
2. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 drug in this class
3. Scilex Pharmaceuticals, Inc. · 1 drug in this class
4. Wolfson Medical Center · 1 drug in this class
5. Zynerba Pharmaceuticals, Inc. · 1 drug in this class